Full Press Release Details
MATERIAL CHANGE REPORT
AETERNA ZENTARIS INC.
Aeterna Zentaris Inc. (the Corporation )
Parc-Technologique Boulevard
Quebec City, Qu bec G1P 4P5
April 2, 2012, the Corporation issued a news release indicating the material change, which was disseminated in Canada on the Canada NewsWire service. A copy of such news release is attached hereto as Schedule A.
On April 2, 2012, the Corporation announced that the Phase 3 X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda ) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
On April 2, 2012, the Corporation announced that the Phase 3 X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda ) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial
involving 468 patients in 65 sites in the U.S was conducted by the Company s North American licensee partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX).
Further information regarding the matters described in this report may be obtained from Dennis Turpin, Senior Vice President and Chief
Financial Officer. Mr. Turpin is knowledgeable about the details of the material change and may be contacted at (418) 652-8525.
Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
QU BEC CITY, April 2, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the Company )
today announced that the Phase 3 X-PECT (Xeloda + Perifosine Evaluation in Colorectal cancer
Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda ) in patients with refractory advanced
colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo. The trial involving 468 patients in 65 sites in the U.S was conducted by the Company s North American licensee partner, Keryx
Biopharmaceuticals, Inc. (NASDAQ: KERX).
Juergen Engel, Ph.D., Aeterna Zentaris President and Chief Executive Officer, commented,
Although we are obviously very disappointed that the trial did not meet its primary endpoint, I would like to thank all those involved in this trial for their dedicated work. We are currently conducting further data analyses in collaboration
with our licensee partners, in order to determine the future development strategy for perifosine. Our other ongoing late-stage programs with AEZS-108 and AEZS-130, as well as earlier-stage programs from our deep pipeline will continue as planned,
with a sufficient cash position to pursue these programs for more than the next 12 months.
The Company will host a conference call and
webcast later today, Monday, April 2, 2012 at 10:00 a.m. (Eastern). Participants may access the live webcast through the Company s website at www.aezsinc.com in the Newsroom section, or by telephone: in Canada,
(514) 807-9895 or (647) 427-7450, outside Canada, (888) 231-8191. A replay of the webcast will also be available on the Company s website for a period of 15 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various cancers. The Company s innovative approach of personalized medicine means tailoring treatments to a patient s specific condition and to unmet medical needs.
Aeterna Zentaris deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
Forward-Looking Statements
release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the
Company s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely
clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials,
the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company s quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company
does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a governmental authority or by applicable law.
For further information:
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406